Antiviral activity of chitosan nanoparticles encapsulating silymarin (Sil–CNPs) against SARS-CoV-2 (<i>in silico</i> and <i>in vitro</i> study)-Reference-Cited by-同舟云学术

Antiviral activity of chitosan nanoparticles encapsulating silymarin (Sil–CNPs) against SARS-CoV-2 (in silico and in vitro study)

Published:2022 Issue:25 Volume:12 Page:15775-15786
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Loutfy Samah A.¹²,Abdel-Salam Ahmed I.²,Moatasim Yassmin³^ORCID,Gomaa Mokhtar R.³,Abdel Fattah Nasra F.¹^ORCID,Emam Merna H.²,Ali Fedaa²,ElShehaby Hasnaa A.⁴,Ragab Eman A.⁴,Alam El-Din Hanaa M.¹,Mostafa Ahmed³^ORCID,Ali Mohamed A.³,Kasry Amal²

Affiliation:

1. Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute (NCI), Cairo University, Fom El-Khalig 11796, Cairo, Egypt

2. Nanotechnology Research Center (NTRC), The British University in Egypt, El-Shorouk City, Suez Desert Road, P. O. Box 43, Cairo 11837, Egypt

3. Center of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Giza 12622, Egypt

4. Biochemistry Dept, Faculty of Science, Cairo University, Egypt

Abstract

To develop a specific treatment against COVID-19, we investigated silymarin–chitosan nanoparticles (Sil–CNPs) as an antiviral agent against SARS-CoV-2 using in silico and in vitro approaches.

Funder

Academy of Scientific Research and Technology

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/RA/D2RA00905F

Reference44 articles.

1. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

2. Re-epithelialization and immune cell behaviour in an ex vivo human skin model

3. Anti-Viral Drugs for Human Adenoviruses